prikaz prve stranice dokumenta A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
  Preuzmi
PDF 1.22 MB
Znanstveni rad - Prikaz slučaja
A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
Journal of Clinical Medicine, 11 (2022), 10; 2779. https://doi.org/10.3390/jcm11102779
Turudić, Daniel; Milošević, Danko; Bilić, Katarina; Prohászka, Zoltán; Bilić, Ernest

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Turudić, D., Milošević, D., Bilić, K., Prohászka, Z. i Bilić, E. (2022). A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review. Journal of Clinical Medicine, 11. (10). doi: 10.3390/jcm11102779

Turudić, Daniel, et al. "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review." Journal of Clinical Medicine, vol. 11, br. 10, 2022. https://doi.org/10.3390/jcm11102779

Turudić, Daniel, Danko Milošević, Katarina Bilić, Zoltán Prohászka i Ernest Bilić. "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review." Journal of Clinical Medicine 11, br. 10 (2022). https://doi.org/10.3390/jcm11102779

Turudić, D., et al. (2022) 'A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review', Journal of Clinical Medicine, 11(10). doi: 10.3390/jcm11102779

Turudić D, Milošević D, Bilić K, Prohászka Z, Bilić E. A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review. Journal of Clinical Medicine [Internet]. 14.05.2022. [pristupljeno 23.11.2024.];11(10). doi: 10.3390/jcm11102779

D. Turudić, D. Milošević, K. Bilić, Z. Prohászka i E. Bilić, "A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review", Journal of Clinical Medicine, vol. 11, br. 10, Svibanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:714954. [Citirano: 23.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:714954
Podaci o radu
Naslov (engleski)A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
AutorDaniel Turudić
AutorDanko Milošević
AutorKatarina Bilić
AutorZoltán Prohászka
AutorErnest Bilić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PEDIJATRIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Pedijatrija
Sažetak (engleski)
Acute lymphoblastic leukemia (ALL) is considered a possible risk for the occurrence of thrombotic microangiopathies. We present a girl with pre-B ALL successfully treated according to the BFM ALL IC-2009 protocol on maintenance therapy followed by aHUS occurrence. This is the seventh case of HUS/aHUS on ALL maintenance therapy and the first with clearly documented eculizumab use in the early stage of aHUS/secondary TMA. Standard and additional parameters were used in aHUS monitoring alongside the reticulocyte production index adjusted for age (RPI/A) and the aspartate aminotransferase-to-platelet ratio index (APRI) as markers of hemolysis and rapid response following treatment. RPI/A and APRI are markers of bone marrow response to anemia serving as red blood cell vs. platelet recovery markers. Together they mark the exact recovery point of thrombotic microangiopathy and serve as a prognostic marker of eculizumab treatment success. During the 8-month treatment and 6-month follow-up, no recurrence of hemolysis, ALL relapse, or renal damage were observed. A systematic review of the literature revealed 14/312 articles; five children had aHUS before the onset of ALL, and two children had both diseases concurrently. At least 3/7 patients are attributed to aHUS, of whom 2/7 have renal damage. Potential undiagnosed/unpublished cases may be assumed.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Clinical Medicine
Brojčani podacivol. 11, br. 10, 2779
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11102779
URN:NBNurn:nbn:hr:105:714954
Datum objave publikacije2022-05-14
URL dokumentahttps://www.mdpi.com/2077-0383/11/10/2779
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-12-14 07:56:01